|
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria
|
Feb 2014
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Performance characteristics of consensus approaches for small and minor paroxysmal nocturnal hemoglobinuria clone determination by flow cytometry.
|
Jun 2013
|
Clin Chem Lab Med
|
myelodysplastic syndromes (MDS)
|
|
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia
|
Sep 2017
|
Exp Hematol
|
aplastic anemia
|
|
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia
|
Sep 2017
|
Exp Hematol
|
aplastic anemia
|
|
Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?
|
May 2015
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
|
Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia
|
Jun 2016
|
Cancer Res.
|
myelodysplastic syndromes (MDS)
|
|
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
|
Sep 2019
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research
|
myelodysplastic syndromes (MDS)
|
|
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
|
Aug 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes
|
Jan 2017
|
Cancer
|
myelodysplastic syndromes (MDS)
|
|
Phase I trial of SAR103168, a novel multi-kinase inhibitor,in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes
|
May 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
